Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Lei Lei Wu

News Reporter

CHICAGO — Self-described “blunt pharma executives” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Phase 3 or bust: Why Lil­ly won't run mid-stage can­cer tri­als

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Oma­da Health is go­ing pub­lic on Fri­day at a $1.1B val­u­a­tion

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

Omada Health is going public on Friday at a $1.1B valuation

Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation

FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees

Trump's health appointees pledge support for cell and gene therapies at FDA roundtable

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...